Tuesday, November 24, 2009

Free Web Seminar - Leveraging Health: Driving Dividends through Value-Based Reimbursement Designs in More Costly Drug Delivery Products

Pin It Now!
Date/Time: Thu, Dec 3, 2009 2:00 PM - 3:00 PM EST

Register: https://www1.gotomeeting.com/register/215966568
Mention priority code P1578W2BlogTwitter

No matter how the reform legislation comes to pass, the ultimate outcomes must focus on health, productivity and economic improvement for the communities we serve. The Center for Health Value Innovation, through a grant from Takeda Pharmaceuticals, has prepared an overview of the levers of value-based design and a coordinated decision matrix for companies to consider as they revise their health plans for 2010 and beyond.

Through a suite of levers focused on prevention and wellness, chronic care management and care delivery, plan sponsors of all sizes, self-insured and fully-insured, can identify plan designs, incentives and disincentives that will shift populations to better health behaviors. How the plan sponsor chooses, and what questions are asked, is detailed in a forthcoming report. This webinar will frame the decisions and timelines for dividends in their companies and their communities.

What you will learn:
a. What levers will drive better engagement of the consumer, the plan sponsor and the delivery system and result in improved outcomes?
b. Where do we start? What if we are fully insured and cannot get integrated data—what do we do? What if we are a public entity, or working with unions, or operating under legislative barriers—is value based design still possible?
c. What are reasonable expectations? What are the timelines for achievement and key messages for the C-Suite?
d. How do we work with our vendors and health plans to promote, engage, and measure the outcomes?

Presenters:
Cyndy Nayer, Co-Founder and CEO, Center for Health Value Innovation
Ray Zastrow, MD, Vice President, Center for Health Value Innovation

Wednesday, November 18, 2009

Web Seminar: Insights and Perspectives from the FDA Public Hearing on the Use of Social Media and Internet for Health-Related Communications

Pin It Now!
Title: Insights and Perspectives from the FDA Public Hearing on the Use of Social Media and Internet for Health-Related Communications

Date: Wednesday, December 9, 2009
Time: 12:00 PM - 1:00 PM EST

Register here:
https://www1.gotomeeting.com/register/668144112

Mention priority Code: P1506W12Blog

About the web seminar:

The FDA Social Media and Internet Public Hearing November 12-13, 2009 posed many questions for the pharmaceutical and biotech industries. Hear impressions of the event in a live interview with Jonathan Richman, Director of Business Development, Bridge Worldwide (Hearing Speaker) and Mel Halkyard, Global eCapabilities Director, Eli Lilly (Hearing Attendee)

What You Will Learn:
- Potential policy and regulatory actions from the FDA as a result of the hearing
- Major obstacles and challenges presented by the industry due to lack of guidance
- Solutions suggested by the industry to address current issues with internet and social media

Presented By:
Jonathan Richman, Director of Business Development
Bridge Worldwide

Mel Halkyard, Global e-Capabilities Director
Eli Lilly & Company

Monday, November 16, 2009

What Does the Future Hold for ePharma?

Pin It Now!
John Sharp from the eHealth blog recently covered an article from Read Write Web in which Google CEO Eric Schmidt talked about a future dominated by Chinese Language and social media content. Here are some key points that will have a direct effect on the pharma.

  • Five years from now the internet will be dominated by Chinese-language content.
  • Today's teenagers are the model of how the web will work in five years - they jump from app to app to app seamlessly.
  • Five years is a factor of ten in Moore's Law, meaning that computers will be capable of far more by that time than they are today.
Perhaps five years from now everyone will be running on mobile watch-sized computing devices. It will be interesting to see over the course of the next 5 years where technology will lead the pharma industry to.

Friday, November 13, 2009

FDA Hearings Underway in DC

Pin It Now!
Yesterday, the FDA began their two day hearing discussing how Pharma companies can interact and market their products on the internet. The hearing is to determine whether or not the FDA needs to incorporate themselves more into regulating how marketing is done on the internet. Many drug companies are saying there are many websites that currently have information about about drugs on their websites, but are failing to incorporate the entire picture. For the meeting, which could hold a maximum of 350, there were over 800 applicants who joined the meeting. Read more here.

Were you able to attend the meeting? Is the mass numbers of people wanting to attend the meeting surprising to you? Or is the fact that the FDA has waited this long to conduct the hearings even more surprising?

Thursday, November 12, 2009

Drug industry presses FDA to allow more online ads

Pin It Now!
The Associated Press writes that the Food and Drug Administration will convene a two-day meeting beginning Thursday to hear the drug industry's position on Internet marketing. The agency has agreed to consider developing rules for online advertising after companies complained that the current guidelines for traditional media — which require a detailed list of possible side effects — have left them hamstrung on the Web.
An estimated 83 percent of Internet users search for health information online, according to a recent survey from the Pew Research Center.

A few drugmakers have begun trying to reach patients via social networking sites like Facebook and YouTube. But overall the industry's online presence trails other sectors, including retail, financial services and computer makers.

What do you think the outcome will be for pharma? We'd like to hear your thoughts.

Wednesday, November 11, 2009

Intel Releases its Own "Text" Reader for the Health Care Market

Pin It Now!
This post in the NY Times highlights a new handheld device unveiled by Intel called the IntelReader that helps people who struggle to read standard texts because of certain medical conditions. The reader is able to scan books and other printed texts into a digital form, and then read it aloud to its users.

The device, which is priced at 1$,500, is far less than any other text-to-speech devices covered by Medicare that range from $5,000 - $10,000. Intel is also looking into making other devices in the health care market as it is trying to find more uses for its chips other than regular PCs. It will be interesting to see the line-up of health care products Intel will manufacture of the course of the next couple of years.

Tuesday, November 10, 2009

AstraZeneca is joining the conversation

Pin It Now!
In a recent article at Delaware Online, the reveal how and why AstraZeneca is jumping into the social media conversation. Earl Whipple, the Senior Director of AstraZeneca's Corporate Communications Group, is the senior editor of the AZ Health Connections blog, has used the blog to communicate about a variety of topics, including healthcare reform, innovation, and the current state of Pharma and using online technologies.

Many have criticized the new AstraZeneca blog. How do you feel about it? As the article pointed out, people are online and talking about AstraZeneca whether or not their online. This gives them a chance to join the conversation and show their views. What do you think of their blog?

Wednesday, November 4, 2009

Novo Nordisk re-launches hemophilia campaign

Pin It Now!

Evelyn Lee of NJBiz.com reports that New Jersey-based pharmaceutical company, Novo Nordisk has relaunched it's hemophilia campaign. Its “changing possibilities in hemophilia” campaign with a re-branded Web site and a new community on the social networking site Facebook. The new online resources are intended to reach the hemophilia inhibitor community, which represents just 800 to 900 Americans, according to the health care company, whose U.S. headquarters are based in Princeton.

Do you think that Novo Nordisk's relaunch will be a success?